Rockwell Medical (RMTI) Upgraded to “Buy” by ValuEngine
Rockwell Medical (NASDAQ:RMTI) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.
Separately, Ifs Securities upgraded shares of Rockwell Medical from an “outperform” rating to a “strong-buy” rating in a report on Monday.
RMTI stock opened at $6.42 on Tuesday. Rockwell Medical has a twelve month low of $2.19 and a twelve month high of $6.77.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC grew its holdings in shares of Rockwell Medical by 23.2% in the fourth quarter. Jane Street Group LLC now owns 36,472 shares of the company’s stock worth $82,000 after purchasing an additional 6,870 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Rockwell Medical by 4.7% in the fourth quarter. Bank of New York Mellon Corp now owns 244,130 shares of the company’s stock worth $552,000 after purchasing an additional 10,863 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Rockwell Medical in the fourth quarter worth about $27,000. BlackRock Inc. grew its holdings in shares of Rockwell Medical by 0.4% in the fourth quarter. BlackRock Inc. now owns 3,233,156 shares of the company’s stock worth $7,306,000 after purchasing an additional 11,911 shares during the last quarter. Finally, Rehmann Capital Advisory Group grew its holdings in shares of Rockwell Medical by 20.9% in the fourth quarter. Rehmann Capital Advisory Group now owns 72,755 shares of the company’s stock worth $164,000 after purchasing an additional 12,563 shares during the last quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.
About Rockwell Medical
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
Featured Article: Why are gap-down stocks important?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.